FDA intends to expand program in January 2027 to all novel drug and biologics applications
The FDA intends to expand the program in January 2027 to all novel drug and biologics applications, broadening the program's reach and impact.
The FDA intends to launch a pathway in early 2027 to expedite applicants' ability to request minimally redacted action packages for approved and licensed drugs and biologics already on the market in the United States.
Sources behind this report
- U.S. Food and Drug Administration
Primary source · U.S. public domain
Source published
Read by the newsroom
Report history
No earlier revision dates are retained here. This does not establish that the report has never changed; read any dated updates and corrections.
This brief was made by AI and checked against its cited public sources. How the newsroom works